Saturday 17 October 2026 Export ZOMDF’s income statement to Excel — free account

Zomedica Corp.

Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.6%, EPS grew 49.3% and free cash flow grew 40.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.08 0.00 0.00%

Follow ZOMDF

Alert me

Market cap: $95.4M
P/E: 0.0×
Fwd P/E: −1.9×
Dividend yield: —
F-score: 4/9
Altman Z: 0.42
Beneish M: −5.04
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.22

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	—	—	—	—	—	6	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.76%

Capital & Financial Ratios $m

Market Cap 95.35

Revenue 36.88

Net Income (18.95)

Free Cash Flow (15.03)

Net Debt (44.13)

Current Ratio 6.43

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.85)

P/S ratio 2.13

P/B ratio 0.73

Past 5Y EPS Growth —

This Y EPS Growth (37.14%)

Next Y EPS Growth 37.50%

Next Y revenue growth 41.52%

Next 5Y EPS Growth 8.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 11.55%

10-year low 10-year high

P/B against its own 10 years 29.06%

10-year low 10-year high

EV/Sales against its own 10 years 7.23%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	90	71	53	44
Receivables	2	3	3	6
Inventory	5	5	6	6
Other	—	—	—	—
	100	82	64	58

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	—	—	—
Other	0	0	0	0
	9	9	9	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	19.16%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	42.20%	17.71%	(24.43%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	10	—	—	—
’25	7	7	8	10	32
’24	6	6	7	8	27
’23	5	6	6	7	25
’22	4	4	5	6	19

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(3)	—	—	—
’25	(7)	(5)	(5)	(1)	(18)
’24	(8)	(7)	(5)	(5)	(24)
’23	(4)	(4)	(3)	(5)	(16)
’22	(2)	(4)	(3)	(2)	(12)
’21	(3)	(2)	(5)	(5)	(14)
’20	(2)	(6)	(6)	(3)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(3)	—	—	—
’25	(7)	(6)	(5)	(1)	(19)
’24	(10)	(8)	(6)	(7)	(30)
’23	(9)	(6)	(10)	(7)	(31)
’22	(3)	(4)	(4)	(3)	(14)
’21	(3)	(2)	(5)	(5)	(15)
’20	(2)	(6)	(6)	(3)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.00	0.00	—	—	—
’25	(0.07)	(0.01)	(0.01)	0.00	(0.08)
’24	(0.01)	(0.02)	(0.01)	(0.01)	(0.05)
’23	(0.01)	(0.01)	0.00	(0.02)	(0.04)
’22	0.00	(0.01)	(0.01)	0.00	(0.02)
’21	0.00	0.00	(0.01)	0.00	(0.05)
’20	(0.02)	(0.02)	(0.01)	(0.01)	(0.05)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	1.88	1.04	0.20	0.06	0.25	0.15	0.15	0.12	0.02	Analyst estimates 2026–2028 Powerpack
	High	—	2.47	2.98	1.27	0.50	2.91	0.50	0.34	0.20	0.16
People
People	Employees	20	20	27	28	19	47	85	144	152	141
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.09	0.22	0.17	0.18	0.23
Income, $m
Income, $m	Revenue	—	—	—	—	—	4	19	25	27	32
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	73.89	71.15	68.76	69.95	67.68
	EBT	(6)	(8)	(17)	(20)	(17)	(21)	(19)	(36)	(48)	(82)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(501.26)	(102.38)	(142.38)	(174.23)	(256.43)
	Net income	(6)	(8)	(166)	(20)	(17)	(18)	(17)	(35)	(47)	(82)
	Depreciation	0	0	2	1	1	1	3	4	6	7
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03	0.03	0.03
	Earnings	(0.07)	(0.09)	(0.18)	(0.19)	(0.05)	(0.05)	(0.02)	(0.04)	(0.05)	(0.08)
	Cash flow	(0.06)	(0.08)	(1.19)	(0.15)	(0.04)	(0.01)	(0.01)	(0.02)	(0.02)	(0.02)
	Capex	0.00	0.00	(0.07)	(0.01)	0.00	0.00	0.00	(0.02)	(0.01)	0.00
	Free cash flow	(0.06)	(0.08)	(1.26)	(0.15)	(0.04)	(0.02)	(0.01)	(0.03)	(0.03)	(0.02)
	Book value	0.05	0.05	0.04	0.02	0.14	0.28	0.27	0.24	0.20	0.12
	Shares, m	80	87	93	106	364	957	980	980	980	980
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	71.75	8.28	7.39	4.31	3.06
	P/B	—	—	—	—	—	1.09	0.59	0.78	0.60	0.85
	EV/Sales	—	—	—	—	—	24.70	2.23	3.82	1.71	1.41
	EV/FCF	—	—	—	—	—	(6.90)	(2.89)	(3.06)	(1.54)	(2.43)
Cash, $m
Cash, $m	Operating cash flow	(5)	(7)	(111)	(16)	(16)	(14)	(12)	(16)	(24)	(18)
	Capex	0	0	(6)	(1)	0	(1)	(3)	(15)	(7)	(1)
	Free cash flow	(5)	(7)	(118)	(16)	(16)	(15)	(14)	(31)	(30)	(19)
Balance, $m
Balance, $m	Working capital	3	3	1	0	62	196	116	91	72	55
	Total debt	—	—	—	—	1	0	1	—	—	—
	Net debt	(3)	(3)	(2)	(1)	(61)	(195)	(115)	(90)	(71)	(53)
	Shareholders’ equity	4	4	4	2	51	271	267	240	196	115
Returns, %
Returns, %	ROA	(141.12)	(164.74)	(295.98)	(387.30)	(48.09)	(29.10)	(6.08)	(12.96)	(20.40)	(48.96)
	ROIC	(588.92)	(538.08)	(603.60)	(780.19)	0.00	(17.59)	(9.00)	(18.09)	(25.67)	(84.84)
	ROE	(158.39)	(196.20)	(413.91)	637.28	(82.10)	(31.32)	(6.32)	(13.61)	(21.57)	(52.63)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$79.8M	—	—	+24.41%	—	−21.18%	54.99%	(44.67%)

All 149 Medical Devices stocks →

Zomedica Corp. (ZOMDF) key facts

Strength: Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024.
Zomedica Corp. (ZOMDF) is a Medical Devices company in the Healthcare sector.
As of October 16, 2026, ZOMDF traded at $0.08, a market capitalization of $95.4 million.
Return on equity was −52.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.